Adlai Nortye (ANL) Net Income towards Common Stockholders (2024)
Adlai Nortye's (ANL) quarterly Net Income towards Common Stockholders came in at -$10000.0 in Q4 2024.
Adlai Nortye (ANL) Net Income towards Common Stockholders (2024) Analysis & Trends
Adlai Nortye (ANL) has 1 years of Net Income towards Common Stockholders data on file, last reported at -$10000.0 in Q4 2024.
- On a quarterly basis, Net Income towards Common Stockholders changed N/A year-over-year to -$10000.0 in Q4 2024; TTM through Dec 2025 was -$10000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at -$35.5 million, up 31.5% from the prior year.
- Net Income towards Common Stockholders for Q4 2024 stood at -$10000.0.
- Over the last five years, Net Income towards Common Stockholders for ANL reached as high as -$10000.0 in Q4 2024 and fell as low as -$10000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | -0.68 |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Adlai Nortye | 1.17 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -10,000.00 |